應(yīng)江蘇省分子醫(yī)學(xué)生物技術(shù)重點(diǎn)實(shí)驗(yàn)室劉暢教授的邀請(qǐng)，美國(guó)輝瑞制藥有限公司旗下心血管、代謝和內(nèi)分泌疾病研發(fā)部高級(jí)科學(xué)家周穎江博士來我校訪問，并做學(xué)術(shù)報(bào)告。
報(bào)告題目：The Crosstalk between ER Stress and Insulin Signaling
報(bào)告人：周穎江 博士 （美國(guó)輝瑞制藥有限公司）
時(shí)間：2012年12月13日 10:00
地點(diǎn)：生命科學(xué)學(xué)院三樓圓形會(huì)議室
報(bào)告人簡(jiǎn)歷：周穎江，男，博士，美國(guó)輝瑞制藥有限公司高級(jí)科學(xué)家。2000年在南京大學(xué)獲得學(xué)士學(xué)位，2005年在南京大學(xué)分子醫(yī)藥研究所獲得生物化學(xué)與分子生物學(xué)博士學(xué)位，2005-2008年在美國(guó)密歇根大學(xué)從事博士后研究，2008-2011年在Harvard Medical School 作為研究員從事內(nèi)分泌研究工作，2011年至今在美國(guó)輝瑞制藥有限公司旗下心血管、代謝和內(nèi)分泌疾病研發(fā)部門擔(dān)任高級(jí)科學(xué)家。目前他的研究方向主要集中于機(jī)體內(nèi)質(zhì)網(wǎng)應(yīng)激和胰島素信號(hào)轉(zhuǎn)導(dǎo)交互作用的分子調(diào)控機(jī)制。
部分代表性論文：
1. Zhou Y, Lee J, Reno CM, Sun C, Park SW, Chung J, Lee J, Fisher SJ, White MF,
Biddinger SB, Ozcan U. Regulation of glucose homeostasis through a XBP-1–FoxO1
interaction. Nature Medicine. 2011; 17: 356–65.
2. Zhou Y, Jiang L, Rui L. Identification of MUP1 as a regulator for glucose and lipid metabolism in mice. The Journal of Biological Chemistry. 2009; 284: 11152–9.
3. Cao J, Zhou Y, Peng H, Huang X, Stahler S, Suri V, Qadri A, Gareski T, Jones J, Hahm S, Perreault M, McKew J, Shi M, Xu X, Tobin JF, Gimeno RE. Targeting acylcoA: diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. The Journal of Biological Chemistry. 2011; 286: 41838–51.
4. Sheng L, Cho KW, Zhou Y, Shen H, Rui L. Lipocalin 13 protein protects against hepatic steatosis by both inhibiting lipogenesis and stimulating fatty acid ?-oxidation. The Journal of Biological Chemistry. 2011; 286: 38128–35.
5. Lee J, Sun C, Zhou Y, Lee J, Gokalp D, Herrema H, Park SW, Davis RJ, Ozcan U. p38 MAPK-mediated regulation of Xbp1s is crucial for glucose homeostasis. Nature
Medicine. 2011; 17: 1251–60.
6. Sheng L, Zhou Y, Chen Z, Ren D, Cho KW, Jiang L, Shen H, Sasaki Y, and Rui L. ?NF-kB–inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action. Nature Medicine. 2012; 18: 943–9.
7. Cho KW*, Zhou Y*, Sheng L, Rui L. Lipocalin-13 regulates glucose metabolism by both insulin-dependent and -independent mechanism. Molecular and Cellular Biology. 2011; 31: 450–7. * equal contributions
8. Park SW, Zhou Y, Lee J, Lee J, Ozcan U. Sarco(endo)plasmic reticulum Ca2+-ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity. Proceedings of the National Academy Sciences of the USA. 2010; 107: 19320–5.
9. Park SW, Zhou Y, Lee J, Lu A, Sun C, Chung J, Ueki K, Ozcan U. The regulatory
subunits of PI3K, p85? and p85?, interact with XBP-1 and increase its nuclear
translocation. Nature Medicine. 2010; 16: 429–37.
10. Sharara-Chami RI, Zhou Y, Ebert S, Pacak K, Ozcan U, Majzoub JA. Epinephrine deficiency results in intact glucose counter-regulation, severe hepatic steatosis and possible defective autophagy in fasting mice. The International Journal of Biochemistry & Cell Biology. 2012; 44: 905–13.
版權(quán)與免責(zé)聲明：本網(wǎng)頁(yè)的內(nèi)容由收集互聯(lián)網(wǎng)上公開發(fā)布的信息整理獲得。目的在于傳遞信息及分享，并不意味著贊同其觀點(diǎn)或證實(shí)其真實(shí)性，也不構(gòu)成其他建議。僅提供交流平臺(tái)，不為其版權(quán)負(fù)責(zé)。如涉及侵權(quán)，請(qǐng)聯(lián)系我們及時(shí)修改或刪除。郵箱：sales@allpeptide.com